Streamlining Hematology Denial Appeal Automation

Klivira provides advanced hematology denial appeal automation to accelerate resolution for complex blood disorder treatments, from high-cost factor concentrates to cutting-edge CAR-T cell therapies.

Revenue cycle leaders and prior authorization coordinators in hematology face unique challenges with denied claims, particularly for high-cost specialty drugs and advanced procedures. Manual appeal processes are resource-intensive, prone to errors, and can delay patient access to critical therapies. Klivira's platform addresses these inefficiencies by automating key steps in the appeal workflow.

The Cost of Unmanaged Hematology Denials

Denials for hematology services, especially those involving expensive factor concentrates, novel sickle cell disease therapeutics, and CAR-T cell therapies, represent significant revenue leakage and administrative burden. Without efficient appeal processes, clinics and health systems risk delayed payments and increased rework costs, impacting financial health and patient care continuity.

Key Denial Areas in Hematology

NCCN-compendium gaps: For novel agents in hematologic oncology (e.g., lymphomas, leukemias, multiple myeloma), where payer policies may lag NCCN guidelines.
Hemophilia factor prophylaxis vs. on-demand criteria: Discrepancies in documentation for factor VIII and IX concentrates.
CAR-T eligibility documentation: Gaps in confirming diagnosis, prior-line therapy, or specific clinical criteria for therapies like Yescarta or Kymriah.
Sickle cell specialty drug criteria: Missing evidence for therapies such as voxelotor or crizanlizumab.
Specialty imaging: Lack of supporting clinical rationale for specific diagnostic imaging related to blood disorders.

Klivira's Approach to Hematology Denial Appeal Automation

Klivira's platform integrates a denial-router that leverages normalized CARC/RARC taxonomy to classify hematology-specific denials. This enables precise routing to the correct appeal pathway, factoring in payer-specific requirements and timely-filing windows. Our system is designed to understand the nuances of ASH and NCCN guidelines, critical for evidence-based appeals in this specialty.

Automated Appeal Workflow for Hematology Cases

Targeted Documentation Re-discovery: Utilizes FHIR-based data extraction to pull specific clinical evidence, such as updated factor levels, joint health assessments, bleeding episode tracking, or new imaging results, directly from the EMR.
Guideline-Aware Appeal Letter Generation: Composes appeal letters using payer-specific templates, incorporating relevant ASH guidelines or NCCN criteria for hematologic oncology, and drafting clinician-reviewable letters for clinical-necessity appeals.
Payer-Specific Pathway Selection: Automatically determines the appropriate appeal level (first-level, second-level, peer-to-peer) based on the denial reason and payer policy library, ensuring adherence to submission requirements.
Automated Submission and Tracking: Submits appeals via the payer's accepted channels (portal, fax, PAS-conformant resubmission) and provides real-time status tracking with timely-filing window enforcement.
Outcome Capture and Feedback: Writes appeal outcomes back to the EMR and feeds success patterns into upstream PA submission processes, continuously improving future authorization rates.

Addressing Key Failure Modes in Hematology Appeals

Manual appeal processes are plagued by documentation gaps, incorrect appeal pathway selection, and timely-filing breaches, particularly for complex hematology cases. Klivira's automation directly mitigates these risks through systematic evidence extraction, policy-aware routing, and automated tracking, ensuring consistency and compliance.

Integrating with EMRs for Comprehensive Denial Management

Our platform integrates seamlessly with your existing EMR system, allowing for direct access to patient data, order types, and clinical notes. This ensures that all necessary clinical documentation, from factor level reports to CAR-T pre-treatment workups, is readily available for automated appeal letter generation and evidence submission, minimizing manual chart review.

Frequently asked questions

How does Klivira handle appeals for off-label use of hematology drugs?

For off-label hematology drug use, Klivira's platform can draft clinician-reviewable appeal letters that incorporate peer-reviewed literature citations. The system pulls relevant clinical notes and allows the clinician to review and approve the evidence-backed letter before submission, ensuring compliance with payer requirements.

Can Klivira automate appeals for denials related to CAR-T cell therapy eligibility?

Yes, Klivira automates appeals for CAR-T cell therapy denials by extracting specific documentation from the EMR, such as diagnosis confirmation and prior-line therapy details, as required by NCCN guidelines. This ensures that appeal letters are comprehensive and address the precise eligibility gaps cited in the denial.

How does Klivira ensure timely filing for hematology appeals across different payers?

Klivira's payer-policy library contains specific timely-filing windows for each payer and appeal level. The system automates status tracking and triggers escalations or alerts to prevent timely-filing breaches, ensuring all hematology appeals are submitted within the required deadlines.

What clinical guidelines does Klivira reference for hematology appeal letter generation?

Klivira's policy logic is designed to be aware of established clinical guidelines such as those from the American Society of Hematology (ASH) and the National Comprehensive Cancer Network (NCCN) for hematologic oncology. This ensures that appeal letters are grounded in current, evidence-based medical standards.

Does Klivira's system help identify patterns in hematology denial reasons?

Yes, Klivira's platform captures appeal outcomes and analyzes success patterns by denial reason and payer. This feedback loop helps identify common hematology denial trends, enabling your team to refine upstream prior authorization submissions and reduce future denials.